StonvexLoading…
StonvexStonvexStonvexCore line items from TRNS's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Annual 2025 2025-03-29 | Annual 2024 2024-03-30 | Annual 2023 2023-03-25 | Annual 2022 2022-03-26 |
|---|---|---|---|---|
Revenue | $278.42M | $259.48M | $230.57M | $204.96M |
Operating Income | $17.87M | $19.78M | $16.25M | $14.14M |
Net Income | $14.52M | $13.65M | $10.69M | $11.38M |
EPS (Diluted) | $1.57 | $1.63 | $1.40 | $1.50 |
Total Assets | $385.24M | $287.55M | $195.75M | $177.76M |
Total Liabilities | $98.36M | $62.38M | $96.12M | $91.59M |
Cash & Equivalents | $1.52M | $19.65M | $1.53M | $1.40M |
Free Cash Flow OCF − CapEx | $25.79M | $19.34M | $7.54M | $7.47M |
Shares Outstanding | 9.32M | 8.84M | 7.56M | 7.53M |